Management and outcome of patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era – analysis of the European LeukemiaNet Blast Phase Registry

Brioli A, Lomaia E, Fabisch C, Sacha T, Klamova H, Morozova E, Golos A, Ernst P, Olsson-Stromberg U, Zackova D, Nicolini FE, Bao H, Castagnetti F, Patkowska E, Mayer J, Hirschbühl K, Podgornik H, Paczkowska E, Parry A, Ernst T, Voskanyan A, Szczepanek E, Saussele S, Franke GN, Kiani A, Faber E, Krause S, Casado LF, Lewandowski K, Eder M, Anhut P, Gil J, Südhoff T, Hebart H, Heibl S, Pfirrmann M, Hochhaus A, Lauseker M (2024)

Publication Type: Journal article

Publication year: 2024

Journal

DOI: 10.1038/s41375-024-02204-y

Abstract

Blast phase (BP) of chronic myeloid leukemia (CML) still represents an unmet clinical need with a dismal prognosis. Due to the rarity of the condition and the heterogeneity of the biology and clinical presentation, prospective trials and concise treatment recommendations are lacking. Here we present the analysis of the European LeukemiaNet Blast Phase Registry, an international collection of the clinical presentation, treatment and outcome of blast phases which had been diagnosed in CML patients after 2015. Data reveal the expected heterogeneity of the entity, lacking a clear treatment standard. Outcomes remain dismal, with a median overall survival of 23.8 months (median follow up 27.8 months). Allogeneic stem cell transplantation (alloSCT) increases the rate of deep molecular responses. De novo BP and BP evolving from a previous CML do show slightly different features, suggesting a different biology between the two entities. Data show that outside clinical trials and in a real-world setting treatment of blast phase is individualized according to disease- and patient-related characteristics, with the aim of blast clearance prior to allogeneic stem cell transplantation. AlloSCT should be offered to all patients eligible for this procedure.

Authors with CRIS profile

Involved external institutions

University Hospital Brno Czech Republic (CZ) Institute of Hematology after Prof. R.H. Yeolyan / ՊՐՈՖԵՍՈՐ Ռ.Հ. ՅՈԼՅԱՆԻ ԱՆՎԱՆ ԱՐՅՈՒՆԱԲԱՆԱԿԱՆ ԿԵՆՏՐՈՆ Armenia (AM) Jagiellonian University Medical College Poland (PL) Universität Augsburg Germany (DE) Ludwig-Maximilians-Universität (LMU) Germany (DE) Centre Hospitalier Annecy Genevois France (FR) Ljubljana University Medical Centre (Ljubljana UMC) / Univerzitetni klinični center Ljubljana Slovenia (SI) Universität Leipzig Germany (DE) First Pavlov State Medical University of St. Petersburg Russian Federation (RU) Universitätsmedizin Greifswald / Universitätsklinikum Greifswald Germany (DE) Universitätsklinikum Mannheim Germany (DE) Federal Almazov Medical Research Centre Russian Federation (RU) Instytut Centrum Zdrowia Matki Polki w Łodzi (ICZMP) / Polish Mother’s Memorial Hospital Research Institute Poland (PL) Universitätsklinikum Jena Germany (DE) Centre Léon-Bérard (UNICANCER) France (FR) Szpital Specjalistyczny w Brzozowie Podkarpacki Ośrodek Onkologiczny im. Ks. B. Markiewicza Poland (PL) Pomeranian Medical University / Pomorski Uniwersytet Medyczny w Szczecinie (PMU) Poland (PL) Stauferklinikum Schwäbisch Gmünd Germany (DE) Klinikum Wels-Grieskirchen Austria (AT) Institute of Hematology and Blood Transfusion / Instytut Hematologii i Transfuzjologi (IHiT) Poland (PL) Medizinische Hochschule Hannover (MHH) / Hannover Medical School Germany (DE) Poznan University of Medical Sciences / Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu Poland (PL) Ospedaliero Universitaria di Bologna Policlinico S.Orsola-Malpighi Italy (IT) Klinikum Passau Germany (DE) University Hospital of Toledo / Hospital Universitario de Toledo Spain (ES) Uppsala University Hospital / Akademiska sjukhuset Sweden (SE) University Hospital Olomouc / Fakultní Nemocnice Olomouc Czech Republic (CZ) Onkologische Schwerpunktpraxis Bielefeld Germany (DE)

How to cite

APA:

Brioli, A., Lomaia, E., Fabisch, C., Sacha, T., Klamova, H., Morozova, E.,... Lauseker, M. (2024). Management and outcome of patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era – analysis of the European LeukemiaNet Blast Phase Registry. Leukemia. https://doi.org/10.1038/s41375-024-02204-y

MLA:

Brioli, Annamaria, et al. "Management and outcome of patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era – analysis of the European LeukemiaNet Blast Phase Registry." Leukemia (2024).

BibTeX: Download